The effectiveness of treatment of drug-resistant pulmonary tuberculosis with the use of drugs of the third row

Abstract

The article focuses on the effectiveness of treatment of drug-resistant tuberculosis the causative agent when used in complex therapy of meronem. Meronem - broad-spectrum antibiotic drug in the third group, which is used to treat the most severe patients with tuberculosis of respiratory organs. The greatest efficacy on clinical and radiological data in the main group reached to four months of therapy, which indicates the feasibility of its use in pulmonary tuberculosis with drug resistance of the pathogen. Meronem application in complex chemotherapy can stop the progression of the tuberculous process and increase the efficiency of treatment by the end of the intensive phase. Tolerability is satisfactory.